KalVista Pharmaceuticals, Inc.
NASDAQ:KALVBiotechnology
+$0.00 today
- Market cap
- $1.44B
- Beta
- -0.11
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$2.74
Volume 4.26M
Average 3.47M
KALV EBITDA Margin
EBITDA as a percentage of revenue.
KalVista Pharmaceuticals, Inc.NASDAQ: KALV
EBITDA Margin · Q4 FY2026 · quarter ended Dec 2025
EBITDA Margin at -42.9%
EBITDA Margin was -42.9% in Q4 FY2026. On a trailing-twelve-month basis it was -101.1%.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 3 analysts of 60.0% for the fiscal year ending Dec 2026, up from -204.6% in FY2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- -42.9%+265.3 pp QoQ
- Last fiscal yearDec 2025
- -204.6%— YoY
- LTMDec 2025
- -101.1%— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | — | +264.6 pp | — |
| 3 years | — | +264.6 pp | — |
| 5 years | +264.6 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2026
- -204.6%
- Year-over-year change
- —
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2026 | 2025-12-31 | -204.6% | — |
| FY2025 | 2025-04-30 | — | — |
| FY2024 | 2024-04-30 | — | — |
| FY2023 | 2023-04-30 | — | — |
| FY2022 | 2022-04-30 | — | — |
EBITDA Margin vs competitors
How KALV compares with its peers on the latest reported figures
- KALV's LTM Dec 2025 EBITDA Margin of -101.1% is the 3rd highest of the 9 companies compared; the peer median is -157.1%.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 939.0% | — | — | |
| LTM Mar 2026 | 43.8% | +19.9 pp | +89.5 pp | |
| LTM Dec 2025 | -101.1% | — | — | |
| LTM Mar 2026 | -105.1% | +22.1 pp | -58.4 pp | |
| LTM Mar 2026 | -129.0% | -45.6 pp | -1804.0 pp | |
| LTM Mar 2026 | -185.2% | +738962.6 pp | +3203.1 pp | |
| LTM Mar 2026 | -304.0% | -275.3 pp | — | |
| LTM Mar 2026 | -333.1% | +482.9 pp | +448.9 pp | |
| LTM Mar 2026 | -387.1% | +1063.3 pp | +2084.9 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding KALV) | -157.1% | +22.1 pp | +269.2 pp | |
Competitors are the stored peer set for KALV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Apr 2022 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 | FY2026 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 73.62M |
| Cost of Revenue | 0 | 0 | 86.17M | 0 | 6.08M |
| Gross Profit | 0 | 0 | (86.17M) | 0 | 67.54M |
| Gross Margin | — | — | — | — | 91.7% |
| Research & Development | 70.17M | 80.28M | 86.17M | 71.71M | 55.64M |
| Selling, General & Admin | 26.45M | 30.6M | 54.28M | 116.29M | 183.74M |
| Operating Expenses | 96.61M | 110.87M | 54.28M | 188M | 239.38M |
| Depreciation & Amortization | 564K | 718K | 816K | 941K | 1.45M |
| EBITDA | (80.75M) | (94.37M) | (134.28M) | (173.33M) | (150.62M) |
| EBITDA Margin | — | — | — | — | -204.6% |
| Operating Income | (96.61M) | (110.87M) | (140.45M) | (188M) | (171.84M) |
| Operating Margin | — | — | — | — | -233.4% |
| Interest Income | 1.09M | 2.23M | 3.9M | 6.44M | 8.68M |
| Interest Expense | 0 | 0 | 0 | 5.79M | 19.34M |
| Other Income / Expenses | 14.27M | 17.96M | 5.35M | 7.94M | 420K |
| Income Before Tax | (82.34M) | (92.91M) | (135.1M) | (180.05M) | (171.42M) |
| Pre-Tax Margin | — | — | — | — | -232.9% |
| Income Tax Expense | 0 | 0 | (8.45M) | 3.39M | (7.13M) |
| Net Income | (82.34M) | (92.91M) | (126.64M) | (183.44M) | (164.29M) |
| Net Margin | — | — | — | — | -223.2% |
| EPS (Basic) | (3.36) | (3.33) | (3.44) | (3.69) | (3.23) |
| EPS (Diluted) | (3.36) | (3.33) | (3.44) | (3.69) | (3.23) |
| Weighted Avg Shares | 24.47M | 27.89M | 36.79M | 49.65M | 50.9M |
| Weighted Avg Shares (Diluted) | 24.47M | 27.89M | 36.79M | 49.65M | 50.9M |
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
Intrinsic Alpha fair value
Locked
Current Price
$27.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.